vTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

vTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition

On May 3, 2017, vTv Therapeutics Inc. issued a press release to
announce its financial results for the fiscal quarter ended March
31, 2017.A copy of the press release is attached as Exhibit 99.1
to this current report on Form 8-K and is incorporated herein by
reference.

The information in this report (including Exhibit 99.1) shall not
be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, and
shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of
1933, as amended or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.

Item 5.07 Submission of Matters to a Vote of Security Holders

On May 1, 2017, vTv Therapeutics Inc. (the Company) held its 2017
Annual Meeting of Stockholders (the Annual Meeting).The matters
voted on at the Annual Meeting and the votes cast with respect to
each such matter are set forth below:

(1)

The Companys stockholders elected the nominees listed
below to the Companys Board of Directors, each to serve
for a term to expire at the Companys 2018 annual meeting
of stockholders or until their successors are duly
elected and qualified based on the following results of
the voting:

Director Nominee

For

Against

Withheld

Broker Non-Votes

Jeffrey B. Kindler

27,329,592

880,404

1,813,950

Steven M. Cohen

27,328,162

881,834

1,813,950

John A. Fry

28,110,751

99,245

1,813,950

Paul M. Meister

27,332,829

877,167

1,813,950

Craig C. Parker

28,100,055

109,941

1,813,950

Paul G. Savas

27,337,362

872,634

1,813,950

Noel J. Spiegel

28,112,841

97,155

1,813,950

(2)

The appointment of Ernst Young LLP as our independent
registered public accounting firm for the fiscal year
ending December 31, 2017 was ratified based on the
following results of the voting:

For

Against

Abstain

29,975,121

9,987

38,838

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated May 3, 2017, announcing financial
results for the fiscal quarter ended March 31, 2017


About vTv Therapeutics Inc. (NASDAQ:VTVT)

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

vTv Therapeutics Inc. (NASDAQ:VTVT) Recent Trading Information

vTv Therapeutics Inc. (NASDAQ:VTVT) closed its last trading session 00.00 at 5.29 with 28,476 shares trading hands.